Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2015
At a glance
- Drugs IRX 5183 (Primary) ; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 23 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 26 May 2008 New trial record.